Floatz logo

ONC 206

Ependymoma

Sabine Mueller, MD, PhDSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Ependymoma cohort.

Asset / SponsorPhaseRating
Nivolumab
University of Florida
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Indoximod
Theodore S. Johnson
Phase 2B
Cyclophosphamide
Theodore S. Johnson
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

ONC 206 is also rated in:

grade II meningiomaDormant
CC
Indicative ·
43 / 100
View asset →
central nervous system cancerDormant
CC
Indicative ·
43 / 100
View asset →
spinal cord gliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →